TY - JOUR
T1 - Anti-CD137 monoclonal antibodies and adoptive T cell therapy
T2 - a perfect marriage?
AU - Weigelin, Bettina
AU - Bolaños, Elixabet
AU - Rodriguez-Ruiz, Maria E.
AU - Martinez-Forero, Ivan
AU - Friedl, Peter
AU - Melero, Ignacio
N1 - Publisher Copyright:
© 2016, Springer-Verlag Berlin Heidelberg.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - CD137(4-1BB) costimulation and adoptive T cell therapy strongly synergize in terms of achieving maximal efficacy against experimental cancers. These costimulatory biological functions of CD137 have been exploited by means of introducing the CD137 signaling domain in clinically successful chimeric antigen receptors and to more efficiently expand T cells in culture. In addition, immunomagnetic sorting of CD137-positive T cells among tumor-infiltrating lymphocytes selects for the fittest antitumor T lymphocytes for subsequent cultures. In mouse models, co-infusion of both agonist antibodies and T cells attains marked synergistic effects that result from more focused and intense cytolytic activity visualized under in vivo microscopy and from more efficient entrance of T cells into the tumor through the vasculature. These several levels of dynamic interaction between adoptive T cell therapy and CD137 offer much opportunity to raise the efficacy of current cancer immunotherapies.
AB - CD137(4-1BB) costimulation and adoptive T cell therapy strongly synergize in terms of achieving maximal efficacy against experimental cancers. These costimulatory biological functions of CD137 have been exploited by means of introducing the CD137 signaling domain in clinically successful chimeric antigen receptors and to more efficiently expand T cells in culture. In addition, immunomagnetic sorting of CD137-positive T cells among tumor-infiltrating lymphocytes selects for the fittest antitumor T lymphocytes for subsequent cultures. In mouse models, co-infusion of both agonist antibodies and T cells attains marked synergistic effects that result from more focused and intense cytolytic activity visualized under in vivo microscopy and from more efficient entrance of T cells into the tumor through the vasculature. These several levels of dynamic interaction between adoptive T cell therapy and CD137 offer much opportunity to raise the efficacy of current cancer immunotherapies.
KW - Adoptive T cell transfer
KW - CARTs
KW - CD137 (4-1BB)
KW - Combined immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=84960349832&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84960349832&partnerID=8YFLogxK
U2 - 10.1007/s00262-016-1818-5
DO - 10.1007/s00262-016-1818-5
M3 - Editorial
C2 - 26970765
AN - SCOPUS:84960349832
SN - 0340-7004
VL - 65
SP - 493
EP - 497
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 5
ER -